Base de dados : HANSEN Pesquisa : HANSENIASE VIRCHOWIANA/QUIMIOTER [Descritor de assunto] Referências encontradas : 46 [refinar] Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 3

ir para página

1 / 46

HANSEN

seleciona para imprimir

Id: 27315 Autor: Ganapati, R; Pai, V. V; Shroff, H. J; Gandewar, Kailas. Título: Rate of decline in bacterial index in leprosy; observations after three different chemotherapeutic interventions. Fonte: Int. J. Lepr;65(2):264-266, Jun. 1997. tab, graf. Descritores: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/microbiol Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/microbiol Rifampina/uso terap Ofloxacino/uso terap Localização: BR191.1

2 / 46

HANSEN

seleciona para imprimir

Id: 27297 Autor: Celik, Onur; Yalcin, Sinasi; Gok, Uzeyir; Yavrucuoglu, Emel; Ozturk, Ahmet; Akyol, Ali. Título: Auditory brain stem evoked potentials in patients with leprosy. Fonte: Int. J. Lepr;65(2):166-169, Jun. 1997. tab. Resumo: Nineteen, randomly selected male patients with lepromatous leprosy were evaluated electrophysiologically. All of these patients had long-standing disease and were treated with dapsone alone. There were statistically significant differences between the values obtained in this group of leprosy patients compared to 20 age-matched controls in auditory brain stem evoked potentials (ABEP). The findings are consistent with a pathologic process located mainly between the cochlear nucleus and the lateral lemniscus in the auditory brain stem pathways. It should be emphasized that our patients had long-standing disease which was treated with dapsone. ABEP could very well be different in leprosy patients diagnosed early and treated for relatively short periods with multidrug therapy. Brain stem evoked response audiometry may be useful for evaluating the possibility of brain stem involvement in leprosy. (AU)^ien. Descritores: Hanseníase Virchowiana/diag Hanseníase Virchowiana/quimioter Hansenostáticos/uso terap Localização: BR191.1

3 / 46

HANSEN

seleciona para imprimir

Id: 27278 Autor: Carsalade, Georges-Yves de; Wallach, Daniel; Spindler, Edith; Pennec, Jean; Cottenot, Francois; Flageul, Beatrice. Título: Daily multidrug therapy for leprosy; results of a fourteen-year experience. Fonte: Int. J. Lepr;65(1):37-44, Mar., 1997. graf. Resumo: Between 1980 and 1994, 67 new or relapsing leprosy patients were treated by daily administered multidrug regimens. Tuberculoid patients (23 TT/BT) received either bitherapy [rifampin + dapsone or clofazimine (RMP + DDS or CLO)] or tritherapy [RMP + DDS and/or CLO and/or ethionamide (ETH)] until clinical cure. Lepromatous patients (44 BB/BL/LL) received tritherapy (RMP + DDS and/or CLO and/or ETH) at least until bacteriological negativity. Of the 23 tuberculoid patients only one patient (5%) was cured at 6 months and about 70% needed between 6 and 24 months of treatment to obtain clinical cure (mean 19.5 months). In the 44 lepromatous patients, the achievement of bacteriological negativity was significantly linked to the initial bacterial index (BI), and it occurred after 2 to 7 years (mean 66.5 months) of multidrug therapy (MDT). The average BI decrease per year was 1.1+ during the first year, 0.9+ the second year, and then < 0.5+ per year. Reactional states significantly (p < 0.01) influenced the BI course: reversal reactions (RR) accelerated while erythema nodosum leprosum (ENL) delayed the BI decrease. Three of the 23 (13%) tuberculoid and 19 of the 44 (43%) lepromatous patients (p < 0.02) exhibited a RR and 18 of 44 (41%) lepromatous patients had ENL during MDT. A late RR (LRR) was observed in 1 (5%) and 6 (17%) of our tuberculoid and lepromatous patients, respectively, and 3 (8%) of our lepromatous patients suffered post-MDT ENL. No confirmed relapse has been observed within a follow-up period of 6 months to 7 years and 3 months [59 person-years at risk (PYR)] for TT/BT patients and of 4 months to 5 years and 10 months (100 PYR) for BB/BL/LL patients. When compared to the recommended WHO/MDT, it appears that daily MDT does not increase the clinical or the bacteriological cure rates either at 6 months in paucibacillary tuberculoid patients or at 2d years in multibacillary lepromatous patients. Moreover, as does the WHO/MDT, our regimens show a high frequency of reactional states both during and after treatment. This fact constitutes the main new problem of the actual treatment of leprosy. (AU)^ien. Descritores: Hanseníase Dimorfa/quimioter Hanseníase Virchowiana/quimioter Hanseníase Tuberculóide/quimioter Limites: Humanos Masculino Feminino Localização: BR191.1

4 / 46

HANSEN

seleciona para imprimir Texto Completo-en

Id: 27233 Autor: Rea, Thomas H; Sieling, Peter A. Título: Delayed-type hypersensitivity reactions followed by erythema noodosum leprosum. Fonte: Int. J. Lepr;66(3):316-327, Sept. 1998. tab. Resumo: Reported herein are 13 borderline lepromatous (BL) or subpolar lepromatous (LLs) patients who presented with or developed delayed-type hypersensitivity (DTH) reactions after initiation of antibacterial therapy, but who subsequently developed erythema nodosum leprosum (ENL), the DTH to ENL group. During the same time, three LLs patients had ENL followed by relapse-associated DTH, a significant (p < 0.05) difference in sequence of the two conditions. The DTH to ENL group had statistically significant higher biopsy indexes at the time of diagnosis of the DTH reaction compared with two DTH control groups, 7 multibacillary patients presenting with DTH reactions and 15 BL or LLs who developed DTH reactions after starting treatment but had no ENL. DTH-associated histologic changes were less well developed in the DTH to ENL group than in either of the two control groups. In the DTH to ENL group, 77% required prednisone in addition to thalidomide to achieve a complete remission in contrast to only 10% of 21 ENL clinical controls. In the DTH to ENL group, the classical histologic ENL pattern was present in only 31% of these patients, in contrast to 88% of 33 ENL histologic controls. In 9 of 9 of the DTH to ENL patients studied, after the ENL remitted, Mycobacterium leprae-sonicate-stimulated lymphocyte transformation tests gave stimulation indexes within the range of our tuberculoid (TT) and borderline tuberculoid (BT) patients, in contrast to absent responses in 6 ordinary, longterm-treated patients who had had ENL. (AU)^ien. Descritores: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/imunol Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/imunol Meio Eletrônico: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1998/pdf/v66n3/v66n3a02.pdf - en. Localização: BR191.1

5 / 46

HANSEN

seleciona para imprimir Texto Completo-en

Id: 27144 Autor: Sinha, Sudhir; Mcentegart, Anne; Girdhar, Bhawneshwar K; Bhatia, Amarjit S; Sengupta, Utpal. Título: Appraisal of two mycobacterium leprae specific serological assays for monitoring chemotherapy in lepromatous (LL/BL) leprosy patients. Fonte: Int J Lep;57(1):24-32, Mar. 1989. ^bgraf, ^btab. Resumo: Two of the Mycobacterium leprae-specific assays--a serum antibody competition (for an epitope on 35-kDa protein) test (SACT) and an enzyme-linked immunosorbent assay (ELISA) for the disaccharide epitope of phenolic glycolipid-I (PGDS)--were comparatively evaluated as tools for monitoring chemotherapy in 125 lepromatous leprosy (LL/BL) patients. An adaptation of the SACT from a radioimmunoassay (RIA) to an ELISA procedure is also described. A moderate but statistically significant correlation was observed between the assays, although SACT appeared to be the more sensitive of the two. Levels of antibodies correlated better with the bacterial index (BI) than with the duration of treatment. However, wide individual variations in antibody levels (for a specific duration of treatment or BI) were seen in treated as well as untreated patients. Anti-PGDS antibody response of the IgG type was poorer than that of the IgM type and, apparently, it did not have a bearing on either treatment duration or the BI. Further studies will be needed to clarify whether the treated patients showing a negative (or low) BI and high antibody levels were harboring hidden foci of active infection, and whether treatment could safely be terminated in patients showing low values for both BI and antibody^ien. Descritores: Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/imunol Mycobacterium leprae/imunol Mycobacterium leprae/isol Meio Eletrônico: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n1/v57n1a04.pdf - en.

6 / 46

HANSEN

seleciona para imprimir Texto Completo-en

Id: 26908 Autor: Rea, Thomas H. Título: Trials of Daily, long-term minocycline and rifampin of clarithromycin and rifampin in the treatment of borderlinne lepromatous and lepromatous leprosy. Fonte: Int. J. Lepr;68(2):129-135, Jun., 2000. graf. Resumo: Daily, long-term treatment with minocycline 100 mg and rifampin 600 mg was initiated in 24 previously untreated borderline lepromatous (BL) and lepromatous (LL) patients for a total of 646 patient-months, averaging 26.9 months per patient. The same regimen was started in 12 BL and LL patients having a bacteriologic relapse for a total of 379 patient-months, averaging 32.5 months per patient, and in 12 patients judged to be at high risk for relapse for a total of 354 patient-months, averaging 29.5 months per patient. Daily, long-term treatment with clarithromycin 500 mg and rifampin 600 mg was initiated in 8 previously untreated BL and LL patients for a total of 174 patient-months, averaging 21.8 months per patient. The results in these 56 patients were compared to those obtained in 34 previously untreated BL and LL patients who were treated concurrently receiving daily, long-term dapsone 100 mg and rifampin 600 mg. No evidence of dangerous drug reactions or bone marrow, kidney or liver toxicity was seen in any of these five patient groups. Drug intolerance in 10 of the 90 patients studied necessitated discontinuing the chosen regimen, 4 from rifampin, 3 from dapsone, 2 from minocycline and 1 of undetermined attribution. The use of either minocycline or clarithromycin in conjunction with rifampin appears to pose no great risk when used long term. (AU)^ien. Descritores: Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/imunol Minociclina/uso terap Rifampina/uso terap Claritromicina/uso terap Meio Eletrônico: http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/2000/pdf/v68n2/v68n2a02.pdf - en. Localização: BR191.1

7 / 46

HANSEN

seleciona para imprimir

Id: 25728 Autor: Anon Título: Esquema uniforme de PQT para todos os casos de hanseniase: esboco do protocolo Schedule of uniform MDT for all cases of leprosy: the draft protocol- Fonte: s.l; s.n; 2002. 43 p. tab. Descritores: Hanseníase Dimorfa/quimioter Hanseníase Dimorfa/terap Hanseníase Virchowiana/quimioter Hanseníase Virchowiana/terap Hanseníase Tuberculóide/quimioter Hanseníase Tuberculóide/terap Hanseníase/quimioter Hanseníase/terap Quimioterapia Combinada Limites: Humanos Masculino Feminino Localização: BR191.1; 01138/d.a

8 / 46

HANSEN

seleciona para imprimir

Id: 25273 Autor: Wood, Leonard Título: A statistical analysis of two chemotherapy trials in lepromatous leprosy: I- The response to therapy as measured by inoculation of mice ..- Fonte: s.l; s.n; 1978. 10 p. tab. Resumo: Two recent trials of chemotherapy in relatively large numbers of patients with lepromatous leprosy generated data that permitted analysis of the effects of treatment regimens and of various pretreatment characteristics of the patients. The results of treatment were measured by inoculation of mice with Mycobacterium leprae recovered from skin biopsy specimens obtained from the patients at intervals during the trials. The pretreatment variables-sex, age histopathological and clinical classifications, logarithmic biopsy specimen (LAFB) - were found to be uniformly distributed among the 36 patients treated by regimens 1, 2, 4 and 5 of trial I. . The ten patients treated by regimen 3 were excluded from this analysis. These pretreatment variables were also found to be uniformly distributed among all 21 patients treated by the two regimens of trial II...(AU). Descritores: HANSENIASE VIRCHOWIANA/clas HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/fisiopatol DAPSONA/uso terap RIFAMPINA/uso terap CLOFAZIMINA/uso terap Limites: ESTUDO COMPARATIVO Localização: BR191.1; 0296/S

9 / 46

HANSEN

seleciona para imprimir

Id: 24509 Autor: Gallo, Maria Eugênia Noviski. Título: Comparação de dois esquemas poliquimoterápicos com duração fixa em hanseníase multibacilar / Comparison of two drug therapy projects with multibacillary fixed duration in leprosy Fonte: Hansen. int;(n.esp):141-142, Jun. 1998. . Conferência: Apresentado em: Congresso da Associação Brasileira de Hansenologia, IX, Foz do Iguaçu, 04-08 junho 1997. Descritores: HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/imunol HANSENIASE VIRCHOWIANA/fisiopatol HANSENIASE VIRCHOWIANA/terap HANSENIASE TUBERCULOIDE/quimioter HANSENIASE TUBERCULOIDE/imunol HANSENIASE TUBERCULOIDE/fisiopatol HANSENIASE TUBERCULOIDE/terap - QUIMIOTERAPIA COMBINADA Limites: RELATO DE CASO ESTUDO COMPARATIVO HUMANO Localização: BR191.1

10 / 46

HANSEN

seleciona para imprimir

Id: 22990 Autor: Wood, L Título: A statistical analysis of two chemotherapy trials in lepromatous leprosy ?- Fonte: s.l; s.n; 1978. 4p p. . Resumo: Interrelationships among six patient characteristics recorded upon entry into the trial were analyzed for 67 patients with lepromatous and near-lepromatous leprosy admitted into two chemotherapy trials. Sex was found to be significantly associated with age and with the histopathologic classification; disproportionately large numbers of other patients and of patients classified as bordeline-lepromatous (BL) were males. Classifications of the disease process by clinical and histopathologic criteria were closely associated, but many patients classified BL on histopathological ground were classified fully lepromatous by the clinical criteria. Measurementd of the number of Mycobacterium leprae in the patients made by three methods were also significantly correlated. No significant correlations were found between either classification of the disease process on the one hand, and any of the measurements of the numbers of organisms on the other. Descritores: HANSENIASE VIRCHOWIANA/clas HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/microbiol HANSENIASE VIRCHOWIANA/patol DAPSONA/uso terap RIFAMPINA/uso terap CLOFAZIMINA/uso terap Limites: RELATO DE CASO Localização: BR191.1; 00294/s; BR191.1; 00295/s

11 / 46

HANSEN

seleciona para imprimir

Id: 22342 Autor: S, B. B. M. Dharmendra. Título: Recent advances in the treatment of leprosy. Fonte: Lepr Ind;24(1):4-18, jan., 1952. . Descritores: HANSENIASE TUBERCULOIDE/quimioter HANSENIASE VIRCHOWIANA/quimioter SULFONAS/admin SULFONAS/ef adv SULFONAS/farmacol SULFONAS/tox SULFONAS/uso terap - ACIDO SALICILICO/uso terap  ESTREPTOMICINA/uso terap Localização: BR191.1

12 / 46

HANSEN

seleciona para imprimir

Id: 22248 Autor: Bose, D. N. Título: Joint-Pains in cases of leprosy of the lepromatus type. Fonte: Lepr Ind;15(3):91-91, july, 1943. . Descritores: HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/quimioter Localização: BR191.1

13 / 46

HANSEN

seleciona para imprimir

Id: 22243 Autor: Bose, D. N. Título: Joint-Pains in cases of leprosy of the lepromatus type. Fonte: Lepr Ind;15(3):91-91, july, 1943. . Descritores: HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/quimioter Localização: BR191.1

14 / 46

HANSEN

seleciona para imprimir

Id: 22175 Autor: Davison, A. R. Título: Notes on a case of lymphadenoma complicating leprosy. Fonte: Int. J. Lepr;12(n.esp):38-40, Dec. 1944. tab. Descritores: HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/quimioter HANSENOSTATICOS CHAULMOOGRA/admin CHAULMOOGRA/uso terap DOENCA DE HODGKIN Limites: RELATO DE CASO Localização: BR191.1

15 / 46

HANSEN

seleciona para imprimir

Id: 22143 Autor: Schujman, Salomón; Mercau, Rodolfo. Título: Treatment of leprosy with diphtheria toxoid. Fonte: Int. J. Lepr;10(n.esp):61-67, Dec. 1942. ilus, tab. Resumo: 1- Having become interested in recent favorable reports by other workers on treatment of leprosy with diphtheria toxoid we subjected a group of 11 patients, ten lepromatous and one tuberculoid, to this treatment over a period of five months. 2- None of the patients improved, three remained stationary and eight became worse, clinically and bacteriologically. We therefore decided not to pursue the investigation further. (AU). Descritores: HANSENIASE VIRCHOWIANA/quimioter TOXOIDE DIFTERICO/uso terap Limites: HUMANO Localização: BR191.1

16 / 46

HANSEN

seleciona para imprimir

Id: 22075 Autor: Tarabibi-Castellani, Giovanni; Tarabini-Castellani, Giuseppe. Título: Village - Hansenien S. M. O. M. Ile Alessandra Jilib (Somalie R. D.). Fonte: Acta Lepr;(55-56):65-72, Avril-Sépt. 1974. tab. Resumo: 18 sujets ont été traités par Rifadine à la dose de 600 mg/jour: 3 cas de LL 3 jamais traités, ont présenté une amélioration notable aprés 506 jours de traitment par la Rifadine qui a fait tomber les moyennes des IB et des IM respectivament de 3,4 et 62,5 por cento à 1,6 et l7,7. 5 cas de LL, sulfono-résistants, ont obtenu des résultats cliniques se situant entre bons et excellents après 522 jours de traitment par la Rifadine qui a fait tomber les moyennes des IB et des IM respectivement de 1,9 et 18,3 por cento à 0,9 et 3,5 por cento. 5 cas de LL, jamais traités, ont subi une amélioration notable après 180 jours de traitemt par l`association Rifadine-Sulphorméthoxine administrée en une seule prise hebdomadaire de 2,5 g, qui a fait passer les moyennes des IB et des IM respectivement de 2,2 et 55,5 por cento à 0,9 et 10,9 por cento. 5 cas de LL, dont 3 jamais traités ont reçu pendant 80 jours une associations de Rifadine, d`Etibi (2 g/jour) et de Bactrim (1 g/jour) qui a entrainé une réduction des moyennes des IB et des IM respectivement de 2,3 et 43,5 por cento à 1,89 et 6,7 por cento. Dans tours les cas la Rifadine a été bien tolérée et, vu les bons résultats obtenus, elle mérite d`être soumise à une étude plus approfondie en tant que médicament antihansénien principalement dans les cas de lèpre lépromateuse dont le traitment s`avère difficile (AU). Descritores: HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/prev Localização: BR191.1

17 / 46

HANSEN

seleciona para imprimir

Id: 22068 Autor: Rollier, M. R; Rollier, MM. M. Título: Le traitment à long terme de la lèpre par la Sulfaméthoxypiridazine et la Dapsone. Fonte: Acta Leprol;(55-56):11-19, Avril-Sépt. 1974. tab. Descritores: HANSENIASE DIMORFA/quimioter HANSENIASE VIRCHOWIANA/quimioter HANSENIASE TUBERCULOIDE/quimioter Localização: BR191.1

18 / 46

HANSEN

seleciona para imprimir

Id: 21991 Autor: Rollier, R; Rollier, Mme. M. Título: Essais de traitment des erythèmes noueux lèpreux par le B 663. Fonte: Acta lepr;(40-41):57-76, Juil.-déc. 1970. ilus. Descritores: HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/quimioter Localização: BR191.1

19 / 46

HANSEN

seleciona para imprimir

Id: 21990 Autor: Languillon, J. Título: Action de la thalidomide sur la réaction lépreuse. Fonte: Acta lepr;(40-41):51-55, Juil.-déc. 1970. . Descritores: HANSENIASE VIRCHOWIANA/compl HANSENIASE VIRCHOWIANA/quimioter Localização: BR191.1

20 / 46

HANSEN

seleciona para imprimir

Id: 21987 Autor: Témine, Pierre; Latourelle, Philippe; Bachellerie, Pierre. Título: Explorations immuno-allergologiques chez les lépreux (L.L. ou L.B.) quiescents et réactionnels à l`aide du test de Shelley et du test au latex histamine de mikol. Fonte: Acta lepr;(40-41):27-34, Juil.-déc. 1970. . Resumo: Variuos tests, T.T.L., Shelley`s test, research of histaminopexic power have been used to fix up the role of the bacillus (lepromin) or of the medicationa (D.D.S.) in the leprosy reactions. So far, no results have been obtained with T.T.L. and the Selley`s test, but in the research of histaminopexic power, however, anomalies patients developing leprosy reaction, an allergical state would persist, thought to be subjected to several factor together, allergical ground, bacils attack, and besides, a provocative factor, which thes most often is furnished by the medication (AU). Descritores: HANSENIASE VIRCHOWIANA/quimioter HANSENIASE VIRCHOWIANA/imunol HANSENIASE VIRCHOWIANA/patol Localização: BR191.1

---

página 1 de 3

ir para página

Refinar a pesquisa

Base de dados : HANSEN

Formulário avançado

Pesquisar por : Formulário livre

		Pesquisar	no campo
1			PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
2	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro
3	and or and not		PalavrasPalavras do títuloPalavras do resumoAutorAutor institucionalDescritor de assuntoLimitesIdiomaPaís, ano de publicaçãoRevistaTipo de literaturaNível bibliográficoMonografia em sérieTipo de publicaçãoConferênciaIdentificador únicoLocalizaçãoSuporte eletrônicoData de entradaTipo de registro

Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information